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SUMMARY 
Present study suggest that changes in res|xmse to the post dexamethasone plasma Cortisol levels in the patients of 
major depression receiveing antidepressents (Imipramine and Amitryptyline) might represent a laboratory marker of 
clinital progress. We estimated post dexamethasone plasma Cortisol levels weekly in thirty hospitalized patients 
during pro-treatment, post-treatment and drug .free post-treatment wash out period. In most ol the cases normalization 
of the ]x>st dexamethasone Cortisol levels coincided with clinical improvement and failure to normalize was often 
associated with poorer clinical recovery. No significant difference was observed in the treatment response between 
imipramine and amitryptyline based on post dexamethasone plasma Cortisol levels. 
Monitoring treatment progress in psy-
chiatric disorders have been persistent issue 
to distinguish patients who should respond 
to somatic treatment from those who are 
more appropriately managed by other mo-
des of treatment. A number of recent studies 
have suggested that dexamethasone suppre-
ssion test (post dexamethasone. plasma 
Cortisol level) might serve as an ancillary 
index to predict clinical response and 
outcome in patients receiving antide-
pressant treatment (Carroll, 1972; Dysken et 
al., 1979; Albala and Greden, 1980; 
Goldberg, 1980; Papakostas et al., 1980; 
Holsbocr et al., 1982; Turgum et al., 1982). 
Brown et al. (1980 & 1981) attempted to 
understand whether specific thymoleptic 
drug has preferentially better treatment 
response in depressed patients with ab-
normal response to dexamethasone suppr-
ession test. He found patients with 
evidences of hypothalmic-pituitary-adre-
nal axis hyperactivity as measured by DST 
responded to imipramine or desimipra-
mine, while those with normal DST res-
ponded to amitryptyline or chlorimipra-
mine. However Nelson et al. (1982) failed to 
find significant difference between imipra-
mine and amitryptyline treatment on DST 
results. 
The present study is an attempt to study 
the effect of treatment (imipramine and ami-
tryptyline) and clinical response on the post 
dexamethasone plasma Cortisol level (de-
xamethasone suppression test) and to re-
solve above controversy. 
Materia] and Methods: 
After screening- outpatients in the de-
partment of psychiatry, King George's Me-
dical College and Gandhi Memorial and 
Associated Hospitals, Lucknow, 35 patients 
were selected for present study. After obtai-
ning informed consent they were accepted 
into this study. Patients were hospitalized if 
they met following criteria:(l) age between 
17 to 60 years (2) fulfilling the Research 
Diagnostic Criteria of Major Depression 
(Spitzer et al., 1978) (3) a minimum score of 
17 points on the first 17 items of Hamilton 
Psychiatric Rating Scale for Depression 
(Hamilton, 1960). They were further classi-
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lied according to Internationa) Classification 
of Diseases Ninth revision (WHO, 1977) into 
manic depressive psychosis depressed type 
(296.1) and manic depressive psychosis 
circular type currently depressed (296.3). 
Criteria for exclusion in the study were (1) 
severe physical illness requiring conco-
mitant medication (2) evidences of narrow 
angle glaucoma, prostatic hypertrophy (3) 
history of alcoholism, drug intake such as 
phenytoin sodium, barbiturates, maproha-
mate, glutothemide, mcthaqualonc, carba-
mazepine or cyprohiptadine, (4) evidences 
of endocrinal disorder such as hypopi-
tuitarism, Addison's disease (5) evidences of 
neuropsychiatric: illness such as epilepsy, 
mental retardation and organic brain syn-
drome, (()) High suicidal risk (7) preg-
nancy. Complete physical examination was 
followed by lalxiratory examination to rule 
out systemic disorder. 
Five patients were dropped from the 
study due to various reasons. An equal mim-
lx-r of age and sex matched control subjects 
were selected fulfilling the predefined selec-
tion criteria. 
The patients of experimental group ful-
filling the selection criteria were randomly 
assigned according to random table to 
group-A (Imipraminc) or group B (Amitry-
ptyline) following a drug free observation 
period of 7 days. The patients of both groups 
received a fixed doses of 225 mg/day which 
was achieved within a week starting from 75 
mg/day and continued for six weeks provi-
ded there wcrc-no serious side effects. Sub-
sequent to the completion of treatment, all 
patients in group A ic B were kept free of 
drugs for a period of 7 days post treatment 
washout period so as to nullify effect of anti-
depressant drugs. 
Blood for determination of plasma Cor-
tisol was obtained on weekly interval at 4 
P.M. and 11 P.M. on the day following oral 
administration of 1 mg of dexamethasone. 
Conciding with the weekly measurement of 
plasma Cortisol severity of depression was 
rated on Hamilton Psychiatric Rating Scale 
for Depression and plasma Cortisol was ana-
lysed by the Mattinglay's method (Mat-
tingley, 1962) at Industrial Toxicology Re-
search Centre, Lucknow. 
Results: 
Sajnpk' of the study consists of 30 
depressed patients and 30 controls who com-
pleted the study and were analysed. The 
mean plasma Cortisol levels (yg/dL) for 
depressed patients and controls were 18.08 
(±5.98) and 11.34 (±2.52) respectively. 
Mean plasma Cortisol level is higher in de-
pressed patients as compared to controls and 
it is statistically significant (t=4.81; d.f.=58; 
p<i0.001). 
In the imipraminc group 9 patients out 
of 15 showed improvement whereas 6 did 
not. In amitriptyline group 10 patients out 
of 15 improved and rest 5 did not show im-
provement at the end of treatment period. 
Imipraminc Group: 
In the improved patients there was a sig-
nificant decrease of plasma Cortisol levels in 
post-treatment (t=3.25; d.f.= 8; p<0.05) 
and post-treatment after washout periods 
(t= 2.73; d.f.=8; p<0.05) as compared with 
pretreatment levels. There is some dec-
rease in mean plasma Cortisol level at post-
treatment period but statistically it was 
insignificant. 
In non-improved patients pre-treatment 
post-treatment and post-treatment after 
washout period plasma Cortisol levels were 
19.58 (±6.62),18.93 (±5.88) and 18.44 (±4.72) 
respectively. Differences in plasma Cortisol 
levels during these periods were statistically 
insignificant. 
Amitriptyline Group: 
In improved patients with amitriptyline 
treatment like the imipraminc, there was si-
gnificant decrease of mean plasma Cortisol DST IN MAJOR DEPRESSION  353 
Table-I Mean Plasma Cortisol levels (/x %/dll at various stages of treatment with imipramine and amitrxptvtinc 
Pre-treatment Post-treatment Posl-lrealment after Significance (I'uired'!'test) 
(A) (B) washout period (C.) 
Mean s.ct. Mean s.d. Mean s.d. A \'s 1) A Vs C B Vs C cl.f. 
Imipramine (N—15) 
Improved (N=9) 17.80 
Not Improved (N=(i) 19.58 
4.52 
6.62 
13.43 
18.93 
4.09 
5.88 
12.03 
18.44 
3.97 
4.72 
3.25 
0.99 
2.73 
0.68 
1.55 
0.34 
8 
5 
A mitryptxlinc fN= 15) 
Improved (N=10) 
Not Improved (N=5) 
17.94 
17.00 
6.32 
6.38 
11.98 
15.94 
3.87 
5.49 
12.55 
14.88 
4.21 
5.15 
3.89 
0.99 
2.61 
0.34 
0.81 
0.68 
9 
4 
** - p<0.01., • - p<0.05 
Table-2 Mean plasma Cortisol leivls ( ng /dl) in improved and not improved patients at various stages of treatment 
Pre-trcatment Post-treatment Post-treatment after Significance (Paired t'test) 
(A) <B) washout period (Q 
Mean  s.d.  Mean  Mean  s.d.  AVsB A VsC B VsC cl.f. 
Improved (N=19) 17.87 
Not Improved (N=ll> 18.41 
5.54 
6-63 
12.67 
17.57 
4.04 
5.89 
12.35 
18.82 
4.07 
5.48 
5.13 
2.03 
3.86 
1.25 
0.39 
1.88 
18 
10 
* - pv.0.01." 
levels in post-treatment (t=3.89; d.f.=9; 
p<£0.01) and in post-treatment washout pe-
riod (t=2.61; d.f.=9; p^0.05) as compared 
to pre-trcatment period. 
Decrease in mean plasma Cortisol levels 
in post-treatment after washout period com-
pared to post-treatment level was signifi-
cant (t=0.81; d.f.=9; M.S.). 
Table-2 
In the non improved patients mean 
plasma Cortisol levels were 17.00 (±6.38), 
15.94 (±5.49) and 14.88 (±5.15) respectively. 
The difference in plasma Cortisol levels du-
ring these peroid was insignificant. 
In improved patients mean plasma Cor-
tisol levels in pre-treatment, |x>st-treat-
1 - p<0.001 
ment and post-treatment after washout 
period were 17.87 (±5.54), 12.67 (±4.04), and 
12.35 (±4.07) respectively with a range of 
9.20 to 27.80, 7.05 to 20.75 and 7.20 to 22.45 
respectively. There is significant decrease of 
mean plasma Cortisol level from pre-treat-
ment to post-treatment (t=5.13; d.f. = 13; 
p^O.001) and post-treatment after washout 
period (t=3.86; d.f. = 18; p<0.01). Fall of 
mean plasma Cortisol in post-treatment after 
washout period as compared to post-treat 
ment level was insignificant. 
In contrast there wcrv insignificant 
changes in the mean plasma Cortisol levels 
in pre-treatment, post-treatment and post-
treatment after washout period from pre-
treatment levels. Mean plasma Cortisol in 354  R.GHULAM«aA 
these periods were 18.41 (±6.63), 17.57 
(±5.89) and 18.82 (±5.48) respectively. 
Discussion: 
In the present study the patients re-
ceived iniipraminc or amitriptyline on 
fixed doses ol 225 nig/day which was achie-
ved within a week of starting the treatment 
and continued for a period of 6 weeks which 
means that the patients were treated with an 
adequate doses for adequate period of time. 
Same period of study has also been taken by 
Nelson et al. (1982) and Greden et al. (1983). 
In imipramine treated group (N = 15) 13 
patients received treatment for six weeks 
and the oilier two showed clinical improve-
ment (HRS-D score less than 10) after five 
weeks of treatment. Whereas, in the amit-
riptyline treated group (N = 15) three 
patients received treatment for five weeks 
and 12 patients had to be continued for the 
total study period of six weeks. The response 
rate in the imipramine treated group was 
66% whereas it was 67% in the amitriptyline 
treated group. Almost similar difference in 
the response rate of imipramine and amitri-
ptyline group of treated patients had been 
observed by Cole and Davis in 1975 (70% 
improvement in imipramine group and 75% 
in amitriptyline group). However, Sandifer 
et al. (1965) found no difference after 4 weeks 
of treatment with imipramine or ami-
triptyline in depressed patients. 
The present study failed to demonstrate 
differences in the treatment response bet-
ween imipramine and amitriptyline based 
on pre-treatment hypothalamic-pituitary-
adrenal axis. These findings do not support 
preliminary report by Browm et al. (1980 
and 1981) that dexamethasone suppression 
test predicted good response to the nore-
pinephrine uptake blocking antidepre-
ssants imipramine and desipraniine and 
that dexamethasone suppression predicted 
better response to the serotonin reuptake-
blockers, amitriptyline and chlorimi-
pramine. However, it is also known (Mitre 
et al., 1980) that imipramine and amitri-
ptyline are not pure reuptake blockers of 
norepinephrine and serotonin respectively. 
Because of this lack of specificity of the 
tricyclic antidepressant agent, the findings 
of present study along with that of Nelson et 
al. (1982), are likewise not inconsistent witli 
the hypothesis of central noradrenergic 
inhibition and serotonergic stimulation of 
hypothalamicadrenal axis (Corticotropin 
releasing factor-adrenocor-ticotropine-
hormone-cortisol pathway). 
The mean plasma Cortisol levels in im-
proved and not improved patients on either 
imipramine or amitriptyline treatment 
were compared at pre-treatment, post-
treatment and post-treatment after 7 days 
washout period respectively. In the im-
proved group the mean plasma Cortisol 
level at pre-treatment phase was signi-
ficantly decreased after 6 weeks treatment of 
imipramine or amitriptyline and was equi-
valent to the mean level plasma Cortisol of 
control subjects. Similar was the case for the 
mean value of Hamilton Psychiatric Rating 
Scale for Depression-total score at the end of 
6 weeks treatment period. After 7 days 
post-treatment washout period the mean 
plasma Cortisol level remained more or less 
unchanged, whereas the mean HRS-D total 
score increased from 2.63 to 14.84. 
However, in the not improved group of 
patients the mean plasma Cortisol level du-
ring the pre-treatment phase remained 
more or less unchanged after 6 weeks trea-
tment of either imipramine or amitrip-
tyline and also after a 7 days post-treatment 
washout period. Similarly, the HRS-D total 
scores did not show marked change during 
these three treatment phases. These fin-
dings are in confirmity with that of Brown 
and Shuay (1980), Paykel and Coppen (1979) 
and favour the state dependant nature of 
dexamethasone suppression test on a firm 
footing. 
The present study along with that ol 
Greden et al. (1983), confirm that repeated 
post dexamethasone plasma Cortisol levels DST IN MAJOR DEPRESSION  355 
(DST) have applicability for treatment of 
depr««sives, that in a number of cases they 
progressively normalize with clinical im-
provement, that failure to normalize seems 
to be often associated with poorer clinical 
outcome and that repeated testing is safe and 
well tolerated. A number of potential uses 
for repeated post dexamethasone plasma 
Cortisol levels stem from the present study 
and previously reported data. The first situ-
ation is common; it occurs when a depre-
ssed patient shows clinical improvement du-
ring treatment and the post dexametha-
sone plasma Cortisol levels response is si-
multaneously normalizing. Clinical ratings 
and dexamethasone suppression test re-
sults support each other in this situation, 
and the test confirms clinical impressions 
that the psychotropic medication is effec-
tive and should be continued. Such labora-
tory feed back may be valuable in guiding 
the clinician to continue the treatment. Post 
dexamethasone plasma Cortisol level nor-
malization concomitant with clinical 
remission indicate that antidepressant 
treatment can safely be discontinued. 
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